Report: Number of elderly people with cancer to soar by 80% over next two decades

The number of elderly people being diagnosed with cancer is set to rise by 80% over the next two decades, experts have warned.

About 130,000 people over the age of 75 currently get some form of the disease in the UK each year, but Cancer Research UK has predicted that it could soar to 234,000 by 2035 as a result of an aging population.

With a significant gap in survival rates between Britain and the world's best-performing countries when it comes to older cancer patients, the charity has called on the NHS to do more to ensure it is prepared for the major increase.

Head information nurse Martin Ledwick said: "When elderly people have a lot of health problems and are taking a range of different medications, it can affect what treatment they are able to receive.

"Some older people with cancer might not be fit enough to have surgery and go through lengthy periods of chemotherapy and radiotherapy, but as no two patients are the same, there will be others who are.

"That's why it's so important staff are well trained and resourced so they can assess older people properly and ensure they receive the right treatment, care and support specific to their individual needs."

Women who get breast cancer above the age 75 are far more likely to survive for longer in Europe than they are in the UK and Ireland, and survival rates for bowel cancer in the same age group are 15% lower here than in Canada.

The report suggested the rates were notably lower among older patients in the UK because they were more likely to be diagnosed with cancer at a more advanced stage, making it harder to treat.

Between 2006 and 2015, 41% of all cancers in those aged 80 to 84 were diagnosed in an emergency in England, compared with 14% of cancers in those aged between 50 and 59.

Rose Gray, Cancer Research UK's policy manager, added: "If we do nothing, the disparity in care between older and younger cancer patients will only grow.

"It's vital to address this if we want to realize our ambition of ensuring world-class treatment for everyone in the UK who is affected by cancer."

Source: http://bit.ly/2McysE5

Call for Abstracts: Cancer Diagnosis

Cancer is considered to be the main reason for deaths across the globe. The cure for cancer is still a matter of research. However, there are few curing techniques available only if the person is diagnosed at the early growth stages. So cancer diagnosis becomes a very important part of an individual’s survival.

Since the cancer cells exhibit properties of a normal cell until it reaches malignant stages, it becomes difficult to diagnose. However few symptoms can act as the signals for the cancer growth. Once these symptoms are encountered one will have to undergo diagnosis techniques like Biopsy, Radiography etc… Through these methods, the practitioner will be able to predict the stage of cancer and survivability of the patients.

Some of the tests conducted to diagnose the Cancer are

• Mammography
• Colonoscopy
• MUGA Scan
• Barium Enema
• Sigmoidoscopy
• Tumor Marker Tests
• Biopsy
• Bone Marrow Aspiration and Biopsy
• Computed Tomography (CT) Scan
• Ultrasound
• Upper Endoscopy
• Digital Rectal Exam (DRE)
• EKG and Echocardiogram
• Types of Endoscopy
• Fecal Occult Blood Tests
• Magnetic Resonance Imaging (MRI)
• Bone Scan
• Breast MRI
• Pap Test
• Positron Emission Tomography and Computed Tomography (PET-CT) Scans

Cancer Diagnosis Conferences:

3^rd Cancer Diagnostics & Treatment Conference November 29-December 01, 2018 Dublin, Ireland; International Conference on Cancer Research and Diagnostics August 15-16, 2018 Singapore; International Conference on Cancer Diagnosis & Treatment August 2-3 2018 Oslo, Norway; 36^th World Cancer Conference October 11-13, 2018 Zurich, Switzerland; World Congress on Cancer Science and Therapy November 14-15, 2018 San Antonio, USA; 15^th International Conference on Surgical Pathology and Cancer Diagnosis April 15-16, 2019 Berlin, Germany; 6^th World Congress and Expo on Breast Pathology and Cancer Diagnosis July 25-26, 2018 Vancouver, Canada

Keywords:

Cancer Conferences | Cancer Diagnosis Conferences | Cancer Therapy Conferences | Cancer Science Conferences | Tumor Diagnosis Conferences | Oncology Conferences | Toronto Conferences | Canada Conferences | Meetings | Workshops | Summit | 2019 | Pulsus Conferences | USA Conferences | Europe Conferences | Asia Pacific Conferences

Cancer research BREAKTHROUGH: Scientists reveal promising tumour-killing therapy

Innovation in Cancer Therapy:

Cancer therapies which cut off blood supplies to dangerous tumours could be an effective new way of helping cancer patients, a study has found.

Cutting out the blood supply to tumours, in combination with existing chemotherapeutic drugs, could stop cancer tumours from growing. The ground-breaking research carried out on mice found tumour growth is better-reduced when the Beta3-integrin protein is targeted together with widely used cancer medication. The study, led by researchers at the University of East Anglia (UEA), was published today in the science journal EMBO Reports.

Lead researcher Dr Stephen Robinson, from UEA’s School of Biological Sciences, said: “Tumours must recruit their own blood supply to grow beyond a very small size and this process is called angiogenesis.

“Anti-angiogenic drugs stop tumours from growing their own blood vessels, and this in turn can slow the growth of the cancer, or shrink it.

“Targeting angiogenesis is therefore seen as crucial in many anti-cancer strategies.

“However many anti-angiogenetic therapies target proteins that help the functioning of a patient’s normal blood supply – and this can lead to nasty side effects including haemorrhage, strokes, high blood pressure, and fatigue.”

The researchers now hope to re-energise medical interest in microtubule-targeting agents (MTAs) – protein structures which help cells move and divide and are commonly used in chemotherapy. The scientists found the use of MTAs together with Beta3-integrin targeting is a more successful combo than Beta3-integrin targeting used alone.

Dr Robinson said: "This protein, Beta3-integrin, has been the focus of drug design over the last two decades because its expression is vastly increased in endothelial cells during blood vessel recruitment to tumours.

“We found that targeting the protein Beta3-integrin in combination with the use of microtubule-targeting agents (MTAs) could be a good way to stop tumours recruiting a blood supply to grow.

“This is really important because MTAs are already in clinic and commonly used as chemotherapies such as paclitaxel in cancer patients.

“Meanwhile Beta3-integrin inhibitors have been at the centre of cancer drug design for over 20 years and are well-tolerated in clinical trials.”

“We hope that this research could revitalise interest in this sort of therapy and lead to a re-purposing of MTAs as anti-angiogenic inhibitors, in combination with targeting Beta3 integrin.”

According to Cancer Research UK, more than 360,000 new cancer cases are diagnosed every year, based on 2013 to 2015 figures. In 2015 alone, around 183,000 men were diagnosed with concern and around 177,000 women were diagnosed. Breast, prostate, lung and bowel cancers are the most commonly diagnosed cancers. 2016 statistics reveal around 450 people die every day from cancer – more than quarter of all deaths in the country.

Source: http://bit.ly/2xmchsz

https://www.express.co.uk/

Keywords:

Cancer Research News | Cancer Therapy News | Oncology News | Cancer Conferences in Toronto | Cancer Conferences in Canada | Cancer events | Cancer Meetings | Cancer Summits | Oncology Conferences in Toronto | Oncology Conferences in Canada 

Call for Abstracts: Cancer Diagnosis

Cancer is considered to be the mail reason for deaths across the globe. The cure for cancer is still a matter of research. However there are few curing techniques available only if the person is diagnosed at the early growth stages. So cancer diagnosis becomes a very important part of an individual’s survival.

Since the cancer cells exhibit properties of a normal cells till it reaches malignant stages, it becomes difficult to diagnose. However few symptoms can act like the signals for the cancer growth. Once these symptoms are encountered one will have to undergo diagnosis techniques like Biopsy, Radiography etc… Through these methods practitioner will be able to predict the stage of the cancer and survivability of the patients.

Some of the tests conducted to diagnose the Cancer are-

• Mammography
• Colonoscopy
• MUGA Scan
• Barium Enema
• Sigmoidoscopy
• Tumor Marker Tests
• Biopsy
• Bone Marrow Aspiration and Biopsy
• Computed Tomography (CT) Scan
• Ultrasound
• Upper Endoscopy
• Digital Rectal Exam (DRE)
• EKG and Echocardiogram
• Types of Endoscopy
• Fecal Occult Blood Tests
• Magnetic Resonance Imaging (MRI)
• Bone Scan
• Breast MRI
• Pap Test
• Positron Emission Tomography and Computed Tomography (PET-CT) Scans
• Benefits of screening
• Risks of screening

Abstract submission portal for the "24th Global Meet on Cancer Research and Oncology" is open now. Submit your abstract here at: Abstract Submission

For more details on the conference visit: Cancer Conference

Cancer Diagnosis Conferences | Cancer Diagnosis Events | Cancer Diagnosis Meetings | Cancer Diagnosis Meetings

3rd Cancer Diagnostics & Treatment Conference - November 29-December 01, 2018 Dublin, Ireland (CANCER DIAGNOSTICS 2018); International Conference on Cancer Research and Diagnostics August 15-16, 2018 Singapore (CANCER DIAGNOSTICS CONFERENCE 2018); International Conference on Cancer Diagnosis & Treatment August 2-3 2018 Oslo, Norway (CANCER TREATMENT 2018); International Conferences on Cancer Diagnosis and Treatment Thursday, August 2, 2018 to Friday, August 3, 2018; 36th World Cancer Conference October 11-13, 2018 Zurich, Switzerland (WORLD CANCER 2018); Early diagnosis research conferences; 3rd Oncologist & Cancer Diagnostics Conference 2018 September 20–21, 2018 Germany, Berlin; 2nd Edition of International Conferences on Clinical Oncology and Molecular Diagnostics June 11-13, 2018 Dublin, Ireland (Clinical Oncology 2018)

Cancer Meetings in Canada | Cancer Meetings in Canada | Cancer Events in Canada | Cancer Conferences